PubRank

O Brad Spiller

Author PubWeight™ 26.81‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The relevance of complement to virus biology. Virology 2004 1.29
2 Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J Virol 2005 1.15
3 The Kaposi's sarcoma-associated herpesvirus complement control protein (KCP) binds to heparin and cell surfaces via positively charged amino acids in CCP1-2. Mol Immunol 2006 1.08
4 Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A. J Biol Chem 2002 1.05
5 Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism. J Antimicrob Chemother 2009 1.03
6 Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance. Antimicrob Agents Chemother 2009 1.01
7 Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor. Circulation 2009 0.98
8 Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line. J Virol 2011 0.96
9 Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J Virol 2007 0.94
10 Off to a slow start: under-development of the complement system in term newborns is more substantial following premature birth. Immunobiology 2011 0.93
11 Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int 2002 0.92
12 Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest 2003 0.92
13 Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice. J Infect Dis 2004 0.91
14 The Kaposi's sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system. J Biol Chem 2004 0.89
15 Serum killing of Ureaplasma parvum shows serovar-determined susceptibility for normal individuals and common variable immuno-deficiency patients. Immunobiology 2011 0.89
16 Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity. Thorax 2010 0.89
17 Synergic activation of toll-like receptor (TLR) 2/6 and 9 in response to Ureaplasma parvum & urealyticum in human amniotic epithelial cells. PLoS One 2013 0.86
18 Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP). J Biol Chem 2008 0.85
19 Kaposi's sarcoma-associated herpes virus complement control protein: KCP--complement inhibition and more. Mol Immunol 2006 0.82
20 Viral heparin-binding complement inhibitors--a recurring theme. Adv Exp Med Biol 2007 0.81
21 Mechanism of neutrophil dysfunction: neutrophil serine proteases cleave and inactivate the C5a receptor. J Immunol 2014 0.81
22 Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis. Pediatr Infect Dis J 2014 0.81
23 More recent swine vesicular disease virus isolates retain binding to coxsackie-adenovirus receptor, but have lost the ability to bind human decay-accelerating factor (CD55). J Gen Virol 2005 0.80
24 Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie-adenovirus receptor and alphavbeta5 integrin expression. J Gen Virol 2005 0.80
25 Molecular characterization of the rhesus rhadinovirus (RRV) ORF4 gene and the RRV complement control protein it encodes. J Virol 2007 0.79
26 Prevalent human coxsackie B-5 virus infects porcine islet cells primarily using the coxsackie-adenovirus receptor. Xenotransplantation 2004 0.79
27 Human diffusely adhering Escherichia coli expressing Afa/Dr adhesins that use human CD55 (decay-accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55. Infect Immun 2004 0.78
28 High-resolution melt PCR analysis for genotyping of Ureaplasma parvum isolates directly from clinical samples. J Clin Microbiol 2013 0.78
29 Growth characteristics of human adenoviruses on porcine cell lines. Virology 2008 0.77
30 Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies. Immunology 2007 0.76
31 Monoclonal anti-neutrophil elastase antibody characterisation: ability to block function, detect free versus serpin-complexed enzyme and stain intracellular granules. J Immunol Methods 2008 0.75
32 Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals. Vaccine 2007 0.75